Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors

被引:45
|
作者
Eggener, Scott E.
Carver, Brett S.
Loeb, Stacy
Kondagunta, G. Varuni
Bosl, George J.
Sheinfeld, Joel
机构
[1] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Urol Serv, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[3] Georgetown Univ, Sch Med, Dept Urol, Washington, DC 20057 USA
关键词
retroperitoneal lymph node dissection; salvage therapy; chemotherapy; testicular neoplasms; metastatic;
D O I
10.1002/cncr.22440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Postchemotherapy surgery is an essential component in the management of patients with metastatic germ cell tumors (GCT). The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT. METHODS. By analyzing the institutional prospective surgical database from 1989 to 2004, 71 patients were identified who underwent RPLND after multiple chemotherapy regimens. Clinicopathologic and treatment trends were characterized, and predictors of disease-specific survival (DSS) were evaluated. RESULTS. The histologic findings at RPLND were fibrosis in 36 men (51%), GCT in 20 men (28%), and teratoma in 15 men (21%). Patients who underwent RPLND from 1989 to 1998 (n = 47), compared with patients who under-went RPLND from 1999 to 2004 (n = 24) were more likely to have GCT (36% vs 13%; P = .04). Patients who received taxane-containing chemotherapy regimens as salvage therapy had lower rates of GCT at RPLND (14% vs 42%; P = .01), higher rates of fibrosis (63% vs 39%; P = .04), and similar rates of teratoma (31% vs 33%; P = .9). The 5- and 10-year DSS rates were 74% (95% confidence interval [95% CI], 62-86%) and 70% (95% CI, 56-84%), respectively. Five-year DSS based on worst histology of RPLND and extraretroperitoneal specimens was 87% (95% CI, 75-99%) for fibrosis, 87% for teratoma (95% CI, 63-100%), and 47% for GCT (95% CI, 23-71%; P = .004). On multivariable analysis, retroperitoneal mass >= 5 cm and GCT were predictors of worse DSS (P = .03 and P = .005, respectively). CONCLUSIONS. Taxane-based salvage chemotherapeutic regimens appear to have decreased the rate of GCT at RPLND. The current data support RPLND in select patients after salvage chemotherapy, because a considerable proportion has teratoma or GCT, and the 10-year DSS rate after resection is 70%.
引用
收藏
页码:528 / 535
页数:8
相关论文
共 50 条
  • [1] Pathologic findings and clinical outcomes of patients undergoing retroperitoneal lymph node dissection following multiple chemotherapy regimens for metastatic germ cell tumors
    Eggener, SE
    Carver, BS
    Sharp, DS
    Motzer, RJ
    Bosl, GJ
    Sheinfeld, J
    JOURNAL OF UROLOGY, 2006, 175 (04): : 191 - 191
  • [2] Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymphadenectomy after multiple chemotherapy regimens for metastatic nonseminomatous testicular tumors
    Argirovic, D.
    Stanic, V.
    Argirovic, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 624 - 625
  • [3] Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors
    Muramaki, M
    Hara, I
    Miyake, H
    Yamada, Y
    Okada, H
    Kamidono, S
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (09) : 763 - 767
  • [4] Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour
    Willis, Susan F.
    Winkler, Mathias
    Savage, Philip
    Seckl, Michael J.
    Christmas, Timothy J.
    BJU INTERNATIONAL, 2007, 100 (04) : 809 - 812
  • [5] Nonseminomatous germ cell testicular tumors clinical stage II: Retroperitoneal lymph node dissection, chemotherapy or both?
    Sava, T
    Pessa, S
    Nicoletti, L
    Perin, A
    Fraccon, AP
    Merlin, F
    Rosa-Bian, A
    Fosser, V
    Cetto, GL
    Franceschi, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 442S - 442S
  • [6] Primary retroperitoneal lymph node dissection in pathologic stage in testicular germ cell tumors: A clinicopathological study
    Al-Ahmadie, H
    Olgac, S
    Stasi, J
    Sheinfeld, J
    Reuter, VE
    MODERN PATHOLOGY, 2005, 18 : 125A - 125A
  • [7] Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors
    Spiess, Philippe E.
    Diorio, Gregory J.
    JOURNAL OF UROLOGY, 2017, 197 (02): : 396 - 397
  • [8] CLINICAL OUTCOME OF PATIENTS WITH FIBROSIS/NECROSIS AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED GERM CELL TUMORS
    Mano, Roy
    Carver, Brett
    Bosl, George
    Motzer, Robert
    Bajorin, Dean
    Feldman, Darren
    Sheinfeld, Joel
    JOURNAL OF UROLOGY, 2015, 193 (04): : E112 - E112
  • [9] Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer
    Beck, SDW
    Foster, RS
    Bihrle, R
    Einhorn, LH
    Donohue, JP
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (06) : 423 - 430
  • [10] Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours
    Carsten-Henning Ohlmann
    Matthias Saar
    Laura-Christin Pierchalla
    Miran Zangana
    Alena Bonaventura
    Michael Stöckle
    Stefan Siemer
    Julia Heinzelbecker
    Scientific Reports, 11